Vadadustat(Vafseo)

In 2024, the U.S. FDA approved the prescription drug Vafseo for the treatment of anemia caused by chronic kidney disease in dialysis patients. The drug targets the HIF prolyl hydroxylase (HIF‑PH) subtypes 1, 2, and 3, and should be used strictly under medical supervision.

Target of Action

Subtypes 1, 2, and 3 of HIF prolyl hydroxylase (HIF‑PH).

Dosage and Administration

Route and frequency of administration for Vadadustat: Oral, once daily.

The dosage of Vadadustat should be adjusted based on the patient’s actual condition. For specific details, consult a doctor and use strictly as directed.

Recommended reading: Dosage and Administration of Vadadustat

Side Effects

Common side effects: Hypertension, diarrhea.

Serious side effects: Increased risk of death, myocardial infarction, stroke, venous thromboembolism, and vascular access thrombosis.

Reference article: Side Effects of Vadadustat

Use in Special Populations

Pregnancy: May cause fetal harm.

Lactation: Breastfeeding is not recommended within two days after the last dose.

Daily Precautions

1. Call your doctor at once if you experience sudden numbness or weakness (especially on one side of the body), vision or balance problems, shortness of breath, pain, swelling, or warmth in one leg, or if no vibration is felt at the dialysis access site.

2. Also call your doctor immediately if you have seizures, loss of appetite, nausea, upper right abdominal pain, difficulty swallowing, tiredness, itching, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes), bloody or tarry stools, coughing up blood, or vomit that resembles coffee grounds.

FDA，2024.03